Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations.

[1]  Sally J. Singh,et al.  Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. , 2016, Chest.

[2]  P. Calverley,et al.  Blood eosinophils as a marker of response to inhaled corticosteroids in COPD , 2016, European Respiratory Journal.

[3]  I. Pavord,et al.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.

[4]  J. Wedzicha,et al.  Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[5]  I. Pavord,et al.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.

[6]  J. Lordan,et al.  A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation , 2012, Thorax.

[7]  Meilan K. Han,et al.  Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. , 2014, American journal of respiratory and critical care medicine.

[8]  H. Hoogsteden,et al.  Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[9]  H. Kerstjens,et al.  Stable-State Midrange-Proadrenomedullin Level Is a Strong Predictor of Mortality in Patients With COPD. , 2014, Chest.

[10]  H. Kerstjens,et al.  Stable state MR-proadrenomedullin level is a strong predictor for mortality in COPD patients. , 2013, Chest.

[11]  D. Serisier.  Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. , 2013, The Lancet. Respiratory medicine.

[12]  M. McGuckin,et al.  Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. , 2013, JAMA.

[13]  W. Boersma,et al.  Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. , 2013, JAMA.

[14]  Johny Verschakelen,et al.  Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial , 2013, Thorax.

[15]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[16]  R. Wenzel,et al.  Antibiotic prevention of acute exacerbations of COPD. , 2012, The New England journal of medicine.

[17]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[18]  M. M. van der Eerden,et al.  Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): Study protocol for a randomised controlled trial , 2012, Trials.

[19]  S. Suissa,et al.  Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality , 2012, Thorax.

[20]  C Michael Stein,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[21]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[22]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[23]  G. Hanquet,et al.  Temporal Trends of Invasive Streptococcus pneumoniae Serotypes and Antimicrobial Resistance Patterns in Spain from 1979 to 2007 , 2009, Journal of Clinical Microbiology.

[24]  F. Arena,et al.  Erythromycin Resistance in Streptococcus pyogenes and Macrolide Consumption in a Central Italian Region , 2009, Infection.

[25]  T. Seemungal,et al.  Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.

[26]  J. Struck,et al.  Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. , 2008, Chest.

[27]  H. Goossens,et al.  Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study , 2007, The Lancet.

[28]  S. Bojesen,et al.  C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[29]  P. Calverley,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[30]  J. Jais,et al.  Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial , 2006, Thorax.

[31]  H. Goossens,et al.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study , 2005, The Lancet.

[32]  G. Scheffer,et al.  Emergence and Persistence of Macrolide Resistance in Oropharyngeal Flora and Elimination of Nasal Carriage of Staphylococcus aureus after Therapy with Slow-Release Clarithromycin: a Randomized, Double-Blind, Placebo-Controlled Study , 2004, Antimicrobial Agents and Chemotherapy.

[33]  H. Mukae,et al.  Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. , 2003, Respiratory medicine.

[34]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[35]  Ramon Gisbert,et al.  Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. , 2002, Chest.

[36]  T. Kohyama,et al.  Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. , 1997, American journal of respiratory and critical care medicine.

[37]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.